193 related articles for article (PubMed ID: 12537937)
1. Cytoreductive nephrectomy in metastatic renal cancer.
Flanigan RC
Curr Urol Rep; 2003 Feb; 4(1):36-40. PubMed ID: 12537937
[TBL] [Abstract][Full Text] [Related]
2. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial.
Mickisch GH; Garin A; van Poppel H; de Prijck L; Sylvester R;
Lancet; 2001 Sep; 358(9286):966-70. PubMed ID: 11583750
[TBL] [Abstract][Full Text] [Related]
3. Cytoreductive surgery in the management of metastatic renal cell carcinoma: the UCLA experience.
Franklin JR; Figlin R; Rauch J; Gitlitz B; Belldegrun A
Semin Urol Oncol; 1996 Nov; 14(4):230-6. PubMed ID: 8946623
[TBL] [Abstract][Full Text] [Related]
4. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer.
Flanigan RC; Salmon SE; Blumenstein BA; Bearman SI; Roy V; McGrath PC; Caton JR; Munshi N; Crawford ED
N Engl J Med; 2001 Dec; 345(23):1655-9. PubMed ID: 11759643
[TBL] [Abstract][Full Text] [Related]
5. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis.
Flanigan RC; Mickisch G; Sylvester R; Tangen C; Van Poppel H; Crawford ED
J Urol; 2004 Mar; 171(3):1071-6. PubMed ID: 14767273
[TBL] [Abstract][Full Text] [Related]
6. Nephrectomy and interleukin-2 for metastatic renal-cell carcinoma.
Pantuck AJ; Belldegrun AS; Figlin RA
N Engl J Med; 2001 Dec; 345(23):1711-2. PubMed ID: 11759660
[No Abstract] [Full Text] [Related]
7. Immunotherapy for advanced renal cell cancer.
Coppin C; Porzsolt F; Awa A; Kumpf J; Coldman A; Wilt T
Cochrane Database Syst Rev; 2005 Jan; (1):CD001425. PubMed ID: 15674877
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy with interleukin-2 and alpha-interferon in patients with metastatic renal cell cancer with in situ primary cancers: a pilot study.
Spencer WF; Linehan WM; Walther MM; Haas GP; Lotze MT; Topalian SL; Yang JC; Merino MJ; Lange JR; Pockaj BA
J Urol; 1992 Jan; 147(1):24-30. PubMed ID: 1729540
[TBL] [Abstract][Full Text] [Related]
9. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106
[TBL] [Abstract][Full Text] [Related]
10. The timing of immunotherapy and nephrectomy in multimodality treatment of metastatic renal cell carcinoma.
Bex A; Horenblas S; de Gast GC
Technol Cancer Res Treat; 2003 Jun; 2(3):205-10. PubMed ID: 12779351
[TBL] [Abstract][Full Text] [Related]
11. Metastatectomy prior to immunochemotherapy for metastatic renal cell carcinoma.
Lee SE; Kwak C; Byun SS; Gill MC; Chang IH; Kim YJ; Hong SK
Urol Int; 2006; 76(3):256-63. PubMed ID: 16601390
[TBL] [Abstract][Full Text] [Related]
12. Complete remission of extensive metastatic renal cancer following immunotherapy.
Plowman PN; Costello J; O'Donoghue N
Clin Oncol (R Coll Radiol); 1997; 9(3):176-80. PubMed ID: 9269551
[TBL] [Abstract][Full Text] [Related]
13. The necessity of cytoreductive nephrectomy in patients with metastatic renal cell carcinoma using antiangiogenic targeted therapy after interferon alfa-2b.
Mutlu H; Gündüz S; Büyükçelik A; Yıldız O; Uysal M; Tural D; Bozcuk H; Coşkun HŞ
Clin Genitourin Cancer; 2014 Dec; 12(6):447-50. PubMed ID: 25022784
[TBL] [Abstract][Full Text] [Related]
14. Cytoreductive nephrectomy: past, present and future.
Galazi M; Rodriguez-Vida A; Josephides E; Chau NM; Chowdhury S
Expert Rev Anticancer Ther; 2014 Mar; 14(3):271-7. PubMed ID: 24392671
[TBL] [Abstract][Full Text] [Related]
15. Removing the primary tumor after the cancer has spread.
Tannock IF
N Engl J Med; 2001 Dec; 345(23):1699-700. PubMed ID: 11759650
[No Abstract] [Full Text] [Related]
16. Interleukin-2 immunotherapy followed by resection of residual renal cell carcinoma.
Fleischmann JD; Kim B
J Urol; 1991 May; 145(5):938-41. PubMed ID: 2016805
[TBL] [Abstract][Full Text] [Related]
17. Nephrectomy for metastatic renal-cell cancer.
Copur MS; Ledakis P; Norvell M
N Engl J Med; 2002 Apr; 346(14):1095-6. PubMed ID: 11936126
[No Abstract] [Full Text] [Related]
18. Interferon alpha 2b as medical selection for nephrectomy in patients with synchronous metastatic renal cell carcinoma: a consecutive study.
Bex A; Kerst M; Mallo H; Meinhardt W; Horenblas S; de Gast GC
Eur Urol; 2006 Jan; 49(1):76-81. PubMed ID: 16310929
[TBL] [Abstract][Full Text] [Related]
19. Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial.
Gore ME; Griffin CL; Hancock B; Patel PM; Pyle L; Aitchison M; James N; Oliver RT; Mardiak J; Hussain T; Sylvester R; Parmar MK; Royston P; Mulders PF
Lancet; 2010 Feb; 375(9715):641-8. PubMed ID: 20153039
[TBL] [Abstract][Full Text] [Related]
20. Cytoreductive nephrectomy for metastatic renal cell carcinoma: is it still imperative in the era of targeted therapy?
Pantuck AJ; Belldegrun AS; Figlin RA
Clin Cancer Res; 2007 Jan; 13(2 Pt 2):693s-696s. PubMed ID: 17255295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
